Action TVTX TRAVERE THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Travere Therapeutics, Inc.

Actions

TVTX

US89422G1076

Temps réel estimé Cboe BZX
Autres places de cotation
 15:49:08 03/05/2024 		Varia. 5j. Varia. 1 janv.
6,425 USD +4,30 % Graphique intraday de Travere Therapeutics, Inc. +23,95 % -27,47 %
24/04 CSL Vifor et Travere Therapeutics annoncent que la Commission européenne approuve FILSPARI® (sparsentan) pour le traitement de la néphropathie à IgA CI
03/04 Travere Therapeutics présentera des résumés sur Filspari® (Sparsentan) dans l'Iga Nephropathy au Congrès mondial de néphrologie et à l'American Nephrology Nurses Association CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Travere Therapeutics to Report First Quarter 2024 Financial Results
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI for the treatment of IgA Nephropathy
EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association
North American Morning Briefing : Stocks Set for -2-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics Files Supplemental New Drug Application for Filspari to Treat IgA nephropathy
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI for Treatment of IgA Nephropathy
Travere Therapeutics to Present at Upcoming Investor Conferences
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
Travere Therapeutics Says EMA Committee Recommends Approval of Sparsentan to Treat Kidney Disease
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action TVTX
  4. Actualités Travere Therapeutics, Inc.
  5. Autres langues